SG10201808312YA - Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines - Google Patents

Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Info

Publication number
SG10201808312YA
SG10201808312YA SG10201808312YA SG10201808312YA SG10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA SG 10201808312Y A SG10201808312Y A SG 10201808312YA
Authority
SG
Singapore
Prior art keywords
aluminum salt
enhancing
methods
adsorbed
immunostimulation
Prior art date
Application number
SG10201808312YA
Other languages
English (en)
Inventor
Carl Alving
Jerome Kim
Mangala Rao
Original Assignee
The Government Of The Us Secretary Of The Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The Us Secretary Of The Army filed Critical The Government Of The Us Secretary Of The Army
Publication of SG10201808312YA publication Critical patent/SG10201808312YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG10201808312YA 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines SG10201808312YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969905P 2014-03-25 2014-03-25

Publications (1)

Publication Number Publication Date
SG10201808312YA true SG10201808312YA (en) 2018-10-30

Family

ID=51302762

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808312YA SG10201808312YA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
SG11201607404PA SG11201607404PA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201607404PA SG11201607404PA (en) 2014-03-25 2014-07-09 Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines

Country Status (12)

Country Link
US (1) US20170165358A1 (enExample)
EP (1) EP3122379A1 (enExample)
JP (1) JP2017509713A (enExample)
KR (1) KR20170016315A (enExample)
CN (1) CN106535929A (enExample)
AU (1) AU2014388299A1 (enExample)
BR (1) BR112016021692A2 (enExample)
CA (1) CA2943050A1 (enExample)
MX (1) MX2016012166A (enExample)
RU (1) RU2016141621A (enExample)
SG (2) SG10201808312YA (enExample)
WO (1) WO2015147899A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7385206B2 (ja) * 2018-12-04 2023-11-22 国立大学法人大阪大学 免疫賦活剤
US20230134067A1 (en) * 2020-07-22 2023-05-04 3H Bio. Co., Ltd. A peptide used for immunotherapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
EP1850871A2 (en) * 2005-02-16 2007-11-07 Novartis Vaccines and Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3d-mpl
US20090035360A1 (en) * 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
SG184188A1 (en) * 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine

Also Published As

Publication number Publication date
RU2016141621A3 (enExample) 2018-05-11
MX2016012166A (es) 2017-03-15
US20170165358A1 (en) 2017-06-15
RU2016141621A (ru) 2018-04-25
WO2015147899A1 (en) 2015-10-01
SG11201607404PA (en) 2016-10-28
AU2014388299A1 (en) 2016-10-20
BR112016021692A2 (pt) 2017-08-15
JP2017509713A (ja) 2017-04-06
CN106535929A (zh) 2017-03-22
EP3122379A1 (en) 2017-02-01
CA2943050A1 (en) 2015-10-01
KR20170016315A (ko) 2017-02-13

Similar Documents

Publication Publication Date Title
PH12018500947A1 (en) Crystal form, preparation method and intermediate of dihydropyrido ring compound
PH12017500762A1 (en) Proflavor delivery particles
EP3484448A4 (en) MIMETIC SCAFFOLDS OF CELLS HAVING ANTIGEN AND METHODS OF PREPARING AND USING THEM
SG11202003796XA (en) Zika vaccines and immunogenic compositions, and methods of using the same
SG11201607396WA (en) Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3118204A4 (en) O-phenyl chalcone compound and preparation method and use thereof
MX2017009937A (es) Cepas fungicas y metodos de uso.
MX2017003131A (es) Metodo para la preparacion de 2-alcoxi ciclohexanol.
EP3717511A4 (en) ZIKA VIRUS VACCINES, IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
EP3112351A4 (en) Naphthylamide compound, preparation method and use thereof
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
CA163260S (en) Refill station for toothcleaning apparatus
SG10201808312YA (en) Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
MX2015015428A (es) Eliminacion de riesgo de narcolepsia en vacunas contra influenza.
PH12017501795A1 (en) Pestivirus vaccines for congenital tremors
AU2017219901B2 (en) Methods of immunogenic modulation
ZA201802565B (en) New adjuvant and vaccine composition containing the same
PL3495153T3 (pl) Sposób i urządzenie do wytwarzania materiałów warstwowych z porami synchronicznymi
EP3110261A4 (en) Super critical hydrolysis extraction apparatus and hydrolysis method using the same
HK40103231A (zh) 寨卡疫苗和免疫原性组合物以及其使用方法
HK40103030A (zh) 寨卡疫苗和免疫原性组合物以及其使用方法
HK40030428A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40030429A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40031534A (en) Zika vaccines and immunogenic compositions, and methods of using the same
GB201911959D0 (en) Immunogenic compositions and uses therefor